PU.1 Functions in a Cell-Autonomous Manner to Control the Differentiation of Multipotential Lymphoid–Myeloid Progenitors  by Scott, Edward W et al.
Immunity, Vol. 6, 437±447, April, 1997, Copyright 1997 by Cell Press
PU.1 Functions in a Cell-Autonomous Manner
to Control the Differentiation
of Multipotential Lymphoid±Myeloid Progenitors
Edward W. Scott,*²³ Robert C. Fisher,*²³ Progression through this developmental cascade in-
volves a tightly controlled pattern of gene expressionMarilyn C. Olson,* Eli W. Kehrli,*
that is orchestrated by a complex set of transcriptionM. Celeste Simon,* and Harinder Singh*
factors. Gene targeting in embryonic stem (ES) cells and*Howard Hughes Medical Institute
the generation of ªknockoutº mice has recently beenDepartment of Molecular Genetics
used to examine the functions of various transcriptionand Cell Biology
factors during hematopoiesis. To date, a number of mu-The University of Chicago
tations that result in the loss of one or more hematopoi-Chicago, IL 60637
etic lineages have been reported (Shivdasani and Orkin,
1996).Summary
The ets-family transcription factor PU.1 (Spi-1) is ex-
pressed specifically in hematopoietic tissues, with highTranscription factor PU.1 is required for the develop-
levels of expression in monocytic, granulocytic, and Bment of lymphoid and myeloid progenitors during fetal
lymphoid lineages (Galson et al., 1993; Hromas et al.,hematopoiesis. By generating chimeric animals using
1993; Chen et al., 1995). PU.1 regulates the activity ofPU.12/2 ES cells or PU.12/2 hematopoieticprogenitors,
many lymphoid- and myeloid-specific gene promoterswe demonstrate that PU.1 functions in an exclusively
and enhancers (Moreau-Gachelin, 1994). We havecell-autonomous manner to regulate the development
shown that mutation of the PU.1 gene results in a blockof the lymphoid±myeloid system. Multipotential lym-
to the development of lymphoid and myeloid lineagesphoid±myeloid progenitors (AA4.11, Lin2) are signifi-
in the fetal liver and yolk sac (Scott et al., 1994; Olsoncantly reduced in PU.12/2 embryos and fail to differen-
et al., 1995). However, the generation of erythrocytestiate into B lymphoid or myeloid cells in vitro. These
and megakaryocytes does not require PU.1. Thus, theresults suggest that the lymphoid and myeloid lin-
PU.1 mutation causes a selective loss of lymphoid andeages develop in the fetal liver from a common hema-
myeloid lineages in the hematopoietic system. Its phe-topoietic progenitor not shared with erythrocytes and
notype differs from mutations in genes encoding themegakaryocytes. Finally, the Ikaros gene is expressed
transcription factors SCL/tal-1, GATA-2, AML1, c-myb,in PU.1 mutant embryos, suggesting that PU.1 and
and Ikaros, which have also been shown to be requiredIkaros are independently required for specification of
for the development of multiple hematopoietic lineages.embryonic lymphoid cell fates.
The SCL/tal-1 gene is required for the development of
all hematopoietic lineages and possibly functions to
Introduction specify blood cell fate to the ventral mesoderm (Porcher
et al., 1996). The GATA-2 gene appears to function at
The integrity of the hematopoietic system is maintained the level of the stem cell or multipotential progenitors
by a population of self-renewing pluripotent hematopoi- and is needed for efficient generation of all hematopoi-
etic stem cells (HSCs) that possess the ability to gener- etic lineages (Tsai et al., 1994). Both AML12/2 and
ate the various cell lineages of the blood: erythrocytes, c-myb2/2 embryos produce normal numbers of primi-
megakaryocytes, granulocytes, monocytes, and lym- tive, nucleated erythrocytes in the yolk sac, but exhibit
phocytes. During mouse embryogenesis, primitive he- major defects duringdefinitive hematopoiesis in the fetal
matopoiesis (nucleated erythrocytes) initiates in the yolk liver (Mucenski et al., 1991; Okuda et al., 1996). AML12/2
sac at day 7 of gestation. Starting at day 9, hematopoie- embryos lack all fetal liver-derived hematopoietic cells,
sis gradually shifts to the fetal liver, where definitive whereas c-myb2/2 embryos have a severe reduction of
hematopoiesis (nonnucleated erythrocytes) initiates by all fetal liver-derived lineages except megakaryocytes.
day 11 (Tavassoli, 1991). By birth, HSCs seed the bone The Ikaros gene, in contrast, is specifically required for
marrow, which becomes the primary site of hematopoie- the development of lymphoid lineages and is not needed
sis throughout adulthood. A number of biological activi- for the generation of erythrocytes, megakaryocytes, or
ties have been ascribed to HSCs, including short- and myeloid cells (Georgopoulos et al., 1994). Thus the PU.1
long-term multilineage reconstitution and the radiopro- gene represents a unique regulator of the lymphoid and
tection of lethally irradiated recipient animals (Span- myeloid lineages in the hematopoietic system.
grude, 1994). Lineage-restricted progenitors of the he- In this report, we address several key issues concern-
matopoietic system are considered to be derived from ing the cellular and developmental basis of the multilin-
multipotential intermediates. Therefore, these multipo- eage lymphoid±myeloid defect caused by the PU.1 mu-
tent progenitors represent intermediates between the tation. The block to the development of lymphoid and
HSC and the progenitor cells that are committed to a myeloid progenitors, induced by the PU.1 mutation,
defined lineage (Ogawa, 1993). The identity and lineage could be due entirely to the requirement for PU.1 func-
relationships of the multipotent progenitors remain to tion within such developing progenitors. This would re-
be completely elucidated. flect a cell-autonomous or cell-intrinsic mechanism by
which PU.1 regulates the generation of lymphoid and
myeloid progenitors. Alternatively, PU.1 may execute an²Present address: Institute for Human Gene Therapy, University of
important function in stromal cells of the hematopoieticPennsylvania, Philadelphia, PA 19104.
³These authors contributed equally to this work. microenvironment. In this cell-extrinsic model, failed
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the mutant PU.1 allele. Analysis of spleen and thymus
samples from wild-type mice revealed high-level ex-
pression of PU.1 protein in splenic tissue. Heterozygous
mice reproducibly showed reduced levels of PU.1 pro-
tein in spleen. Importantly, the mutant PU.1 allele did not
express detectable levels of a truncated PU.1 product
containing the N-terminal 198 amino acids. Since the
PU.1 mutation results in late embryonic lethality, we
examined the fetal liver of PU.1 homozygous mutant
embryos for PU.1 protein expression. No PU.1 protein
product was detectable in the fetal liver of homozygous
mutant embryos (Figure 1). As was the case for splenic
tissue, reduced levels of full-length PU.1 protein were
Figure 1. Expression of PU.1 Protein in PU.12/2 Embryos observed in the fetal liver of heterozygotes. Thus the
Protein extracts from the fetal liver of PU.11/1, PU.11/2, and PU.12/2 engineered PU.1 mutation represents a null allele.
littermate embryos (lanes 6±8) were resolved by SDS-PAGE and
probed by Western blotting using an affinity purified anti-PU.1 anti-
serum. Lanes 1 and 2 contained full-length PU.1 and a truncated
PU.12/2 ES Cells Can Contribute to the ErythroidPU.1 protein, respectively, generated by in vitro translation. Lanes
but Not Lymphoid or Myeloid Lineages3±5 contained protein extracts from indicated tissue of PU.11/1 and
PU.11/2 animals. Molecular weight markers are designated at left. of Embryonic Chimeras
To determine whether PU.1 functions in a cell-autono-
mous manner in regulating lymphomyelopoiesis, we
used PU.1 homozygous mutant ES cells to generatestromal cell function caused by the PU.1 mutation would
result in failure to provide proper developmental cues chimeric embryos and animals. The mutant ES cells
were engineered by sequential gene targeting of therequired for the generation of lymphoid and myeloid
progenitors. Finally, a combination of cell-intrinsic and PU.1 locus (Olson et al., 1995). The ES cell line CCE.1,
used for gene targeting, is derived from the 129SVcell-extrinsic mechanisms may underlie the multilineage
defect induced by the PU.1 mutation. In one such sce- mouse strain. Wild-type or PU.12/2 ES cells were in-
jected into C57BL/6 blastocysts to produce control andnario, developing myeloid progenitors could require
PU.1 in a cell-intrinsic mannerand maypromote lympho- experimental chimeras, respectively.To examine thede-
gree of contribution of the ES cells to various tissuespoiesis by a cell-extrinsic mechanism.
We have distinguished among these possibilities by and cell lineages in the chimeras, we took advantage
of genetic polymorphisms in glucose phosphate iso-generating chimeric animals. We demonstrate that PU.1
functions exclusively in a cell-autonomous manner to merase (GPI), hemoglobin (Hbb), and the Ly 9 cell-sur-
face marker.regulate the development of the lymphoid and myeloid
lineages. Furthermore, PU.1 is shown to function at the Initially, the ability of PU.12/2 ES cells to contribute
to hematopoietic lineages in the fetal liver was examinedlevel of multipotential lymphoid±myeloid progenitors,
since such cells are significantly reduced in PU.12/2 in day 16.5 embryonic chimeras. This gestational stage
was chosen because it also facilitated the analysis of Tembryos and do not differentiate into B cells or macro-
phages in vitro. These results suggest that the lymphoid lineage cells in the fetal thymus. Figure 2A shows an
analysis of GPI isoforms in the fetal blood of a controland myeloid lineages develop in the fetal liver from a
common hematopoietic progenitor not shared with and four experimental chimeric embryos(lanes 1±4).The
C57BL/6 host blastocyst±derived cells expressed theerythrocytes and megakaryocytes.
GPIb isoform, whereas the ES cell±derived progeny ex-
pressed GPIc. The control chimera evidenced approxi-Results
mately 50% contribution by the wild-type ES cells. The
experimental chimeras 1 and 2 showed extensive contri-PU.12/2 Embryos Do Not Express
Any PU.1 Protein Product bution by PU.12/2 ES cells to fetal blood cells. This is
due to the mutant cells' ability to generate erythrocytesWe have previously described targeting of the PU.1 gene
in ES cells. Homologous recombination was used to re- but not lymphoid or myeloid cell types (see below). The
overall degree of chimerism revealed by GPI analysis ofplace a segment of exon 5 encoding the C-terminal DNA
binding domain of PU.1 (amino acids 200±272) with the fetal blood was confirmed by Southern blot analysis of
embryonic DNA (data not shown).neo gene (Scott et al., 1994). Analysis of wild-type, het-
erozygous, and homozygous mutant embryos strongly To examine the contribution by ES cell progeny to
erythroid cells in the chimeras, fetal blood was analyzedsuggested that the engineered mutation represented a
loss-of-function allele. To determine whether this muta- for Hbb isoforms. The C57BL/6 blastocyst±derived
erythrocytes express Hbbs, which migrates as a singletion of the PU.1 gene results in loss of expression of the
PU.1 protein product, Western analysis was performed electrophoretic band. The ES cell (129SV mouse strain)±
derived erythrocytes express Hbbd, which migrates aswith affinity-purified anti-PU.1 antibodies (see Experi-
mental Procedures). Figure 1 shows that the anti-PU.1 two bands of lower electrophoretic mobility (Whitney,
1978). PU.12/2 chimeras clearly contained erythrocytesantibodies efficiently recognized both full-length PU.1
protein as well as an N-terminal (amino acids 1±198) derived from homozygous mutant ES cells (Figure 2B,
lanes 1±3). The degree of erythrocyte contribution bysegment, which has the potential to be expressed by
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Figure 2. Analysis of PU.11/1 and PU.12/2 Fetal Chimeras
Wild-type or PU.12/2 ES cells were injected into C57BL/6 blastocysts to produce control and experimental chimeras.
(A) GPI isozyme analysis of fetal liver protein from a wild-type and four PU.12/2 mutant chimeras (lanes 1±4). Extracts from C57BL/6 tissue
(GPIb) and the parental ES cell line CCE.1 (GPIc) were used as GPI standards.
(B) Hbb isoform analysis of fetal blood from chimeric embryos in (A). Blood samples from C57BL/6 and 129SV (ES cell genotype) mouse
strains were used as Hbb standards.
(C) FACS analysis of lymphoid and myeloid cells in wild-type and PU.12/2 mutant embryonic chimeras. Shown are analyses of the wild-type
chimera (left) and the mutant chimera (#2) (right) described in (A). Ly 9.1 staining detects ES cell±derived progeny. Fetal thymocytes were
analyzed using aCD4 (top). Fetal liver B lymphoid and myeloid cells were analyzed using aB220 (middle), and aCD11b (bottom), respectively.
the mutant ES cells correlated with the extent of chime- Thus, loss of PU.1 results in a cell-intrinsic defect
rism as assessed by GPI and Southern blot analyses. during fetal hematopoiesis. PU.1 mutant fetal progeni-
The embryo in lane 4 was shown to be nonchimeric by tors can generate erythrocytes but not lymphoid or my-
both GPI and Southern blot analyses. Thus, as reported eloid progeny. Furthermore, since B220 and Thy 1 are
earlier (Scott et al., 1994), the development of definitive early B and T lineage markers, respectively, and CD11b
erythrocytes in the embryo does not require PU.1. is expressed at the promonocyte stage of monocytic
Flow cytometry was used to examine the ability of development, the block to lymphomyelopoiesis appears
PU.12/2 ES cells to generate lymphocyte and myeloid manifest prior to the generation of committed progeni-
cell types in chimericembryos. ES cell±derived lymphoid tors for each lineage.
and myeloid progeny express the Ly 9.1 cell-surface
marker, thereby distinguishing them from blastocyst-
PU.12/2 ES Cells Fail to Contributederived cells, which are Ly 9.21. Wild-type ES cells con-
to All Hematopoietic Lineagestributed significantly to B lymphoid (B2201, Ly 9.11) and
in Adult Chimeric Micemyeloid (CD11b1, Ly 9.11) cells in the fetal liver and T
The production of chimeric animals with PU.12/2 ESlymphoid (CD41, Ly 9.11) cells in the fetal thymus (Figure
cells overcomes the lethal nature of the PU.1 mutation.2C, left). In contrast, no Ly 9.11 lymphoid or myeloid
This allowed us to investigate the role of PU.1 in lympho-progeny were detectable in multiple chimeras generated
myelopoiesis in the adult bone marrow and thymus. Thewith PU.12/2 ES cells (Figure 2C, right). Fetal thymii of
contribution of wild-type or PU.12/2 ES cells in adultPU.1 mutant chimeras also lacked Ly 9.11, Thy 1.21
chimeras was initially evaluated by the degree of agoutiT lineage progenitors (data not shown). The PU.12/2
coat coloration. All animals selected for further analysisembryonic chimeras recapitulate the lymphoid±myeloid
defects observed in PU.12/2 embryos. showed 50%±70% agouti coloration (ES cells derived
Immunity
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Figure 3. Analysis of PU.11/1 and PU.12/2 Adult Chimeras
Wild-type or PU.12/2 chimeras were generated as described in Figure 2 but analyzed at 4±6 weeks after birth.
(A) GPI isozyme analysis of tissue from representative wild-type and mutant chimeras. Tissues examined were blood (Bld), bone marrow
(BnM), spleen (Spl), thymus (Thy), heart (Hrt), lung (Lng), brain (Brn), muscle (Mus), and kidney (Kid). Arrows indicate positions of GPIb and
GPIc isozymes.
(B) Hbb analysis of peripheral blood from chimeras in (A). Peripheral blood samples from C57BL/6 and 129SV mouse strains were used as
Hbb standards.
(C) FACS analysis of lymphoid and myeloid cells in wild-type and PU.12/2 mutant adult chimeras. Shown are analyses of the wild-type chimera
(left) and the mutant chimera (right) described in (A). Ly 9.1 staining detects ES cell±derived progeny. Thymocytes were analyzed using aCD4
(top). Bone marrow B lymphoid and myeloid cells were analyzed using aB220 (middle) and aCD11b (bottom), respectively.
from the 129SV mouse strain). A total of seven chimeras blood cells. Figure 3B shows that in the control chimera
the red blood cells were derived almost exclusively fromproduced with two independent PU.12/2 ES cell lines
were analyzed along with control chimeras made with input ES cells. In contrast, experimental chimeras (n 5
7) made using PU.12/2 ES cells showed no red bloodwild-type ES cells (CCE.1). At approximately 3 months
of age, chimeras were analyzed for ES cell contribution cell contribution from the input cells. Flow cytometry
analysis confirmed that, as was the case with embryonicto various hematopoietic and nonhematopoietic tissues
by using GPI isoforms. Figure 3A demonstrates that chimeras, PU.12/2 ES cells did not generate lymphoid
or myeloid progeny in adult chimeras. Figure 3C showsPU.12/2 ES cells were essentially equivalent to wild-type
ES cells in contributing to nonhematopoietic tissues fluorescence-activated cell-sorter (FACS) analysis of
lymphoid and myeloid cells in the bone marrow andsuch as heart, lung, muscle, and kidney. However, unlike
their wild-type counterparts, PU.12/2 ES cells showed thymus of control and experimental chimeras. As de-
tailed above, the Ly 9.1 surface marker was used toa greatly diminished capacity to contribute to hemato-
poietic tissues such as blood, bone marrow, spleen, and quantitate the contribution of ES cell±derived progeny.
Wild-type ES cells contributed significantly to B lym-thymus.
The failure of PU.12/2 ES cells to contribute efficiently phoid (B2201, Ly 9.11) and myeloid (CD11b1, Ly 9.11)
cells in the bone marrow as well as to T lymphoid cellsto the peripheral blood of adult chimeras was surprising
given the results obtained with embryonic chimeras (see (CD41, Ly 9.11) in the thymus. No such progeny were
detectable in PU.12/2 chimeras. Identical results wereFigure 2). It suggested that, in addition to the expected
lymphoid±myeloid defect, PU.12/2 hematopoietic pro- obtained by analyzing spleen and peripheral blood of
chimeras (data not shown). These results demonstrategenitors cannotgenerate erythrocytes in adult chimeras.
This conclusion was verified by Hbb analysis of red that PU.1 is required in a cell-autonomous manner for
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Table 1. Radioprotection of Lethally Irradiated C57BL6/Ly5.1 Recipients by PU.11/1 and PU.12/2 Ly5.2
Donor Number of Fetal Livers Number of Animals % Survival Length of Survival
None 0 6 0 7±10 days
PU.11/1 12 12 83 .3 months
PU.12/2 8 26 0 2±3 weeks
Lethally irradiated C57BL6/Ly5.1 mice were reconstituted with 1 3 106 fetal liver cells isolated from Ly5.2 PU.11/1 or PU.12/2 day 16.5 embryos.
Control animals received an equivalent dose of irradiation and no fetal liver cells. Radioprotection results for each donor group are expressed
in terms of percentage survival and length of survival.
the development of lymphoid and myeloid lineages dur- of the two donor PU.12/2 embryos was heterozygous for
Hbb alleles. The contribution to the erythroid compart-ing fetal as well as adult hematopoiesis. They also reveal
an unexpected requirement for PU.1 in adult but not ment of the host by PU.12/2 hematopoietic progenitors
was not due simply to survival of donor erythrocytesfetal erythropoiesis in chimeric animals. Implications of
the differing requirements for PU.1 during fetal and adult and/or differentiation of erythroid progenitors, since
these were removed by osmotic lysis prior to trans-hematopoiesis are elaborated in the Discussion.
plantation.
We next investigated whether the PU.12/2 fetal liverHematopoietic Progenitors from PU.12/2 Embryos
Generate Erythrocytes but Not Lymphoid progenitors (Ly 5.21) could reconstitute the lymphoid
and myeloid lineages of the host animal (Ly 5.11). Figureor Myeloid Cells When Transplanted
into Lethally Irradiated Hosts 4B shows analysis of the bone marrow from recipient
animals at 3 weeks postinjection. Animals (n 5 8) in-PU.12/2 fetal liver±derived hematopoietic progenitors
were assayed for their ability to reconstitute and/or pro- jected with PU.11/1 or PU.11/2 fetal liver cells were re-
constituted for both the B lymphoid (B2201, Ly 5.11)vide radioprotection to lethally irradiated wild-type
hosts. This approach examined the developmental po- and myeloid (CD11b1, Ly 5.11) lineages. Reconstitution
of the T lineage (CD41, Ly 5.21) was just initiating at 3tential of PU.12/2 hematopoietic progenitors in a wild-
type microenvironment. The ability of donor progenitors weeks posttransplantation and therefore could not be
reliably assayed. All animals receiving PU.11/1 orto reconstitute lymphoid and myeloid lineages was as-
sayed by using the Ly 5 cell-surface marker, whereas PU.11/2 cells were reconstituted with donor-derived (Ly
5.11) T cells by 6 weeks postimplantation (data noterythroid reconstitution was examined by analyzing Hbb
expression. Fetal liver cells from PU.11/1, PU.11/2, or shown). The majority of animals that received PU.12/2
fetal liver cells died prior to 3 weeks of transplantation.PU.12/2, day 16.5 embryos (Ly 5.21) were transplanted
into lethally irradiated C57BL6/Ly 5.11 mice. The donor Several animals, however, survived to 3 weeks but ap-
peared unhealthy. Two of these animals were analyzedcells were pre-treated with ACK lysis buffer to remove
erythrocytes (see Experimental Procedures). This treat- for donor-derived lymphoid and myeloid cells in the
bone marrow. No B lineage (B2201, Ly 5.21) or myeloidment was also shown to deplete the donor population
of erythroid burst-forming unit (BFU-E) and erythroid cells (CD11b1, Ly 5.21) arising from PU.12/2 fetal liver
progenitors were detected in these recipients (Figurecolony-forming unit (CFU-E) progenitors in methylcellu-
lose colony-forming assays (data not shown). Table 1 4B). However, a significant population of Ly 5.21 donor-
derived cells were present in the bone marrow. Theseshows the results of the radioprotection assay. Animals
transplanted with PU.11/1 or PU.11/2 fetal liver cells sur- results, along with the detection of donor-derived eryth-
rocytes, suggest that PU.12/2 fetal liver progenitors arevived for more than 3 months with no adverse effects.
Mice that received the PU.12/2 fetal liver cells survived capable of homing to and colonizing the bone marrow,
where they undergo differentiation into erythroid but notfor 17±21 days, an average of 1 week longer than control
animals that did not receive any cells. Thus, PU.12/2 lymphoid or myeloid cells.
hematopoietic progenitors extend the survival of irradi-
ated recipient mice but cannot rescue them from le- Multipotential Lymphoid±Myeloid Progenitors
Are Reduced in PU.12/2 Embryos and Failthality.
The ability of PU.12/2 progenitors to extend the sur- To Differentiate In Vitro
To assess directly the effects of the PU.1 mutation onvival of irradiated animals suggested partial reconstitu-
tion of the host hematopoietic system. To determine hematopoietic progenitor cell populations in the fetal
liver, in vitro colony-forming (clonogenic) assays werewhether the donor fetal liver progenitors generated
erythrocytes, the peripheral blood of transplanted ani- performed. Single-cell suspensions were prepared and
then cultured for 5±7 days in methylcellulose mediummals was analyzed for Hbb isoforms. Male and female
PU.11/2 animals had been screened prior to mating to with growth factors that support the proliferation
and differentiation of erythroid, megakaryoid, and mye-ensure that all donor embryos carried at least one Hbbd
allele. Therefore, any erythrocytes derived from donor loid progenitors. Colony type (CFU) and number were
scored by microscopic examination. Colony identity wasfetal liver cells will produce Hbbd. Figure 4A shows analy-
sis of Hbb from the peripheral blood of animals reconsti- confirmed by cytocentrifugation and May-Grunwald-
Giemsa staining. Table 2A shows the results of suchtuted with either wild-type or PU.12/2 fetal liver cells.
PU.1 mutant fetal liver cells efficiently generated eryth- assays performed with PU.11/1, PU.11/2, and PU.12/2
fetal liver cells. Both PU.11/1 and PU.11/2 fetal liversrocytes upontransplantation. It should benoted that one
Immunity
442
Figure 4. Analysis of Transplanted PU.12/2 Fetal Liver Cells in Lethally Irradiated Recipients
Recipient animals were examined 3 weeks after transplanting wild-type or PU.12/2 fetal liver cells.
(A) Hbb isoform analysis of peripheral blood from irradiated animals transplanted with the indicated donor fetal liver cells. Peripheral blood
samples from C57BL/6 and 129SV mouse strains were used as Hbb standards.
(B) FACS analysis of recipient bone marrow reconstituted with either PU.11/1 or PU.12/2 fetal liver cells. Ly 5.2 staining indicates donor-
derived cells. B lymphoid and myeloid cells were analyzed using aB220 and aCD11b antibodies, respectively.
contained an equivalent distribution of erythroid, mega- individual fetal livers and screened for CD11bbright ex-
pression by FACS. Genotypes were confirmed by South-karyoid, and myeloid progenitors. PU.12/2 fetal livers,
ern blot analysis. PU.11/1 and PU.11/2 fetal liver samplesin contrast, contained normal numbers of erythroid and
were examined individually or as pools. The AA4.11,megakaryoid progenitors (CFU-E, CFU-Meg, and CFU-
Lin2 population constituted 0.5% of day 14.5 fetal liverEMeg) but completely lacked myeloid progenitors
cells isolated from either PU.11/1 or PU.11/2 embryos.(CFU-M, CFU-G, and CFU-GM).
The PU.12/2 fetal liver cells (n 5 3) were found to containGiven the block to myeloid and lymphoid differen-
a significantly reduced fraction (0.1%) of AA4.11, Lin2tiation induced by the PU.1 mutation, we wanted to
cells. The AA4.11, Lin2 cells were analyzed for hemato-determine whether the defect was manifest at the level
poietic progenitor activity in methylcellulose culturesof multipotential lymphoid±myeloid progenitors. Sev-
(Table 2B). The AA4.11, Lin2 populations from both wild-eral groups have devised enrichment procedures for
type and PU.11/2 fetal livers were greatly enriched forlymphoid±myeloid multipotential progenitors from both
myeloid and megakaryocytic progenitors versus un-the fetal liver and yolk sac, based on expression of
sorted cells (compare Tables 2B and 2A). As expectedthe cell-surface marker AA4.1 (McKearn et al., 1984;
with this assay system, PU.12/2-derived AA4.11, Lin2Cumano et al., 1992; Huang and Auerbach, 1993). An
cells contained only megakaryocytic progenitors, butAA4.11 fetal liver population that lacks lineage-specific
no myeloid progenitors.differentiation markers (B220, CD11b, Gr-1) has been
The day 14.5 AA4.11, Lin2 fetal liver population wasshown to be enriched for multipotent progenitors of the
also examined for B cell progenitor activity in vitro by
lymphoid and myeloid lineages as well as HSCs (Jordan
using an assay developed by Cumano and Paige (1992).
et al., 1990; Cumano et al., 1992; Huang and Auerbach, Sorted AA4.11, Lin2 cells were placed on an S17 stromal
1993). Cumano et al. (1992) have additionally demon- cell feeder layer in the presence of the interleukin 7
strated, in vitro, the presence of a bipotential B-cell/ (IL-7). Control cultures were plated on S17 cells alone
macrophage progenitor within the AA4.11, Lin2 popula- or with IL-7 alone. The cultures were then monitored
tion. We used flow cytometric sorting to isolate an for cellular proliferation and differentiation. AA4.11, Lin2
AA4.11, Lin2 population from day 14.5 PU.11/1, PU.11/2, cells from either wild-type or PU.11/2 fetal livers prolifer-
and PU.12/2 fetal livers (see Experimental Procedures). ated onS17 stroma in response to IL-7 (Table 3). Prolifer-
This population of cells was B2202, CD3e2, CD42, CD52, ation was dependent on the presence of both S17 cells
CD82, Gr-12, Ter-1192, and CD11b2/dim. CD11bdim cells and IL-7, since little or no proliferation was detectable
were included in the multipotential progenitor popula- in cultures containing S17 cells or IL-7 alone. FACS
tion since this lineage marker is expressed at low levels analysis was used to examine the surface phenotype of
in fetal HSCs (Morrison et al., 1995). To identify PU.12/2 theproliferating cells. 94% of thePU.11/1 orPU.11/2cells
in the proliferating AA4.11, Lin2 cultures expressedembryos, single-cell suspensions were prepared from
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Table 2. Hematopoietic Colony-Forming Activity
Average Number of Colonies/105
PU.1 Genotype Number of Samples E E-Meg Meg GEMM GM M G
(A) Day 15.5 Fetal Liver Cells
1/1 10 20 10 10 55 45 45 50
1/2 21 15 10 5 50 50 60 40
2/2 14 20 10 15 0 0 0 0
(B) Day 14.5 AA4.11/Lin2 Fetal Liver Cells
1/1 or 1/2 5 0 0 192 250 785 5150 150
2/2 4 0 0 150 0 0 0 0
(A) Day 15.5 whole fetal liver suspensions (2 3 105) prepared from PU.11/1, PU.11/2, and PU.12/2 embryos or (B) sorted AA4.11/Lin2 cells
isolated from individual or pooled PU.11/1, PU.11/2, and PU.12/2 fetal liver cells were plated at a density of 500 cells/dish (2000 total cells
per sample) in a-methylcellulose supplemented with penicillin/streptomysin, L-glutamine, b-mercaptoethanol, erythropoietin, and pokeweed
mitogen stimulated spleen cell conditioned medium. After 5±7 days of incubation, colonies were scored as CFU-E (erythroid), CFU-EMeg
(erythroid-megakaryocytes), CFU-Meg (megakaryocytes), CFU-M (macrophage), CFU-GM (granulocyte-macrophage), and CFU-GEMM (granu-
locyte-erythroid-macrophage-megakaryocytes) and expressed as CFU/105 fetal liver cells.
AA4.1, 87% expressed B220; 7% were surface IgM1; or differentiation of a lymphoid-restricted progenitor
and 13% expressed Mac-1 (CD11b/CD18). These cells (Georgopoulos et al., 1994). Since Ikaros regulates the
also expressed the B lineage±specific genes mb-1 and development of a subset of the lineages controlled by
B29 (data not shown). Thus, as expected, the AA4.11, PU.1, it was of interest to determine the consequences
Lin2 progenitors from PU.11/1 or PU.11/2 embryos were of the PU.1 mutation on Ikaros gene expression in the
able to differentiate into B lineage cells in the presence fetal liver. Figure 6 shows the results of reverse tran-
of S17 and IL-7. We next examined the B cell progenitor scription polymerase chain reaction (RT-PCR) analysis
activity of the AA4.11, Lin2 population isolated from day with fetal liver RNA from PU.11/1, PU.11/2, and PU.12/2
14.5 PU.12/2 fetal livers. Figure 5 shows that PU.12/2- embryos. Ikaros transcripts were readily detectable in
derived AA4.11, Lin2 failed to proliferate in response PU.12/2 embryos. In contrast, expression of the Pax-5
to IL-7 and stromal cell contact. Therefore, the PU.1 gene was eliminated in the PU.12/2 embryos. Pax-5 en-
mutation significantly reduces the fraction of AA4.11, codes a transcription factor required for differentiation
Lin2 progenitors in the fetal liver and blocks their ability of B lineage progenitors (Urbanek et al., 1994). Loss
to proliferate and differentiate into lymphoid or myeloid of Pax-5 expression in PU.12/2 embryos could be due
cells. entirely to the absence of B lineage progenitors. Thus,
the failure to generate lymphoid progenitors in PU.12/2
The Ikaros Gene Is Expressed embryos appears not to be due to the loss of Ikaros
in PU.12/2 Embryos expression.
On the basis of its unique mutant phenotype, the Ikaros
gene has been suggested to control the development Discussion
Targeted disruption of the PU.1 gene results in late (day
18) embryonic lethality and a developmental block in
Figure 5. Frequency Analysis of B Lineage Progenitors in the
AA4.11, Lin2 Population of PU.11/1 and PU.11/2 or PU.12/2 Embryos
Fetal liver cells from day 14.5 littermates were sorted to obtain the
AA4.11, Lin2 populations as described in Experimental Procedures.
Figure 6. Analysis of Ikaros and Pax-5 Expression in PU.12/2 Em-Purified progenitors were plated at 5, 20, 60, 100, or 200 cells/well
bryosin 96-well plates containing irradiated S17 cells and IL-7; 48 wells
were used for each cell density. Wells were scored for proliferating Fetal liver RNA from PU.11/1, PU.11/2, or PU.12/2 littermate embryos
(day 16.5) was analyzed by RT-PCR using primers specific for Ikaros,cells after 9 days in culture. Results for PU.11/1 and PU.11/2
(squares) or PU.12/2 (diamonds) AA4.11, Lin2 progenitors are repre- Pax-5, and hprt transcripts. RNA from the pre±B cell line 38B9 was




Table 3. Proliferation and Differentiation of Day 14.5 AA4.11/Lin2 Fetal Liver Cells on the S17 Stromal Cell Line in the Presence of IL-7
Surface Staining (% Positive)
PU.1 Genotype Growth Conditions Cell Recovery (3 104) AA4.1 B220 sIgM Mac-1
1/2 or 1/1 S17 Ð Ð Ð Ð Ð
(n 5 2) IL-7 0.5 Ð Ð Ð Ð
S17 1 IL-7 56 94 87 7.1 13
The sorted AA4.11/Lin2 fractions from day 14.5 PU.11/1 or PU.11/2 fetal livers were plated at a cell density of 1 3 104/ml in 96-well plates.
Cells were also plated in IL-7 or on S17 cells alone. After 6±7 days in culture, cell viability was quantitated by trypan blue exclusion and cell
surface phenotype characterized by single-color FACS using MAbs specific for AA4.1, B220, sIgM, and Mac-1. The results shown above are
for AA4.11/Lin2 isolated from either single or pooled PU.11/1 or PU.11/2 fetal livers.
the generation of myeloid and lymphoid progenitors in their ability to generate erythrocytes in embryonic chi-
meras. Furthermore, PU.12/2 fetal hematopoietic pro-the yolk sac, fetal liver, and thymus (Scott et al., 1994;
genitors can generateerythrocytes upontransplantationOlson et al., 1995). The PU.1 mutation does not have a
into adult irradiated recipients. The disparity in erythroiddetrimental effect on all hematopoietic lineages, how-
contribution may reflect differing requirements for PU.1ever, since there are normal numbers of megakaryo-
in adult versus fetal liver hematopoietic progenitors. Var-cytes and erythroid progenitors in both the yolk sac and
ious functional and phenotypic differences have beenfetal liver. These initial studies raised the possibility that
described between fetal and adult HSCs, including thePU.1 may be required for the differentiation of a common
following: fetal HSC have superior reconstitution ability;lymphoid±myeloid progenitor. Suchmultipotent progen-
fetal HSC can generate Vl31 and Vl41 T cells but adultitors have been envisioned to represent developmental
HSCs cannot; and fetal HSC express low levels ofintermediates downstream of the HSC and to retain the
Mac-1 (CD11b/CD18) but adult HSC are Mac-12 (Mor-capacity to differentiate along multiple lineages (Uchida
rison et al., 1995). These differences in the HSC compart-et al., 1993). The PU.12/2 phenotype differs significantly
ment of the fetal liver and bone marrow may be de-from GATA-2, rbtn2/LMO2, and SCL/tal-1 knockouts,
termined by differential expression or functioning ofwhich are thought to block or impair primitive HSC func-
transcription factors. Our results suggest that adulttion or survival (Tsai et al., 1994; Warren et al., 1994;
HSCs or their multipotential progenitors, unlike their fe-Robb et al., 1995; Shivdasani et al., 1995). Knockout
tal counterparts, are dependent on PU.1 function.mice with primitive HSC defects die between days 9
Alternatively, it is possible that the lack of PU.12/2 ESand 11 of embryogenesis due to a severe anemia re-
cell contribution to erythropoiesis in adult chimeras issulting from the absence or near absence of erythropoie-
due to differences in HSC cycling rates between bonesis in the yolk sac. The PU.12/2 embryos survive past
marrow and fetal liver. The number of HSCs cycling inthe stage of primitive hematopoiesis in the yolk sac as
the bone marrow has been estimated to be 1%±2%well as definitive hematopoiesis in the fetal liver. The
(Morrison and Weissman, 1994). In recent work on fetallate embryonic lethality induced by the PU.1 mutation
liver HSC, Morrison et al. (1995) estimated that 25%±is not due to failed definitive erythropoiesis (Scott et al.,
30% of the HSC compartment is cycling during fetal1994).
development. If PU.12/2 HSCs are at a competitive dis-The present study characterizes the nature of the de-
advantage to wild-type HSCs, contribution would bevelopmental block caused by mutation of the PU.1 gene
seen more readily during fetal hematopoiesis becauseduring both fetal and adult hematopoiesis. We conclu-
of the larger population of cycling stem cells. However,sively establish that the PU.12/2 defect in lymphomyelo-
the lack of PU.12/2 ES cell±derived erythrocytes in chi-
poiesis iscell autonomous and provide the firstevidence
meras that were 80%±90% ES cell derived in nonhema-
that PU.1 may play different roles in fetal liver versus
topoietic tissues tends to discount this possibility (data
bone marrow hematopoiesis. Two experimental ap-
not shown).
proaches were used to determine whether the PU.12/2 PU.12/2 fetal liver cells were used to reconstitute le-
defect iscell autonomous. Chimeric animals weregener- thally irradiated adult mice in order to examine hemato-
ated with PU.12/2 ES cells and examined as either day poietic progenitor and stem cell function. PU.12/2 fetal
16.5 embryos or adults. This allowed us to investigate liver cells were able only to extend the survival of the
the role of PU.1 in two hematopoietic microenviron- irradiated host animal by an average of 1 week com-
ments, the fetal liver and bone marrow. Embryonic chi- pared to animals that received no cells. The PU.12/2
meras definitively demonstrated a cell-autonomous re- cells were able to colonize the host bone marrow since
quirement for PU.1 during lymphomyelopoiesis (Figure a large number of donor-derived cells (Ly 5.21) were
2). Importantly, mutant hematopoietic progenitors gave present 3 weeks postimplantation (Figure 4B). The lack
rise to definitive erythrocytes in embryonic chimeras. of PU.12/2 donor±derived B lymphoid and myeloid cells
Adult chimeras confirmed the cell-intrinsic role of PU.1 provided an alternate confirmation of the cell autono-
in lymphomyelopoiesis but also revealed that PU.1 may mous nature of the PU.12/2 defect. PU.12/2 fetal liver
be required for erythropoiesis in the bone marrow (Fig- cells contain either HSC or progenitor cells capable of
ure 3). colonizing the bone marrow and differentiating into
The inability of PU.12/2 ES cells to contribute to the erythrocytes (Figure 4). This activity may indicate that
PU.12/2 fetal HSCs are able to colonize and differentiateerythroid lineage in adult chimeras is intriguing, given
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in the bone marrow. Alternatively, it may represent colo- occurs in the absence of PU.1. Indeed it is equally likely
nization, limited proliferation, and differentiation by that early myeloid genes such as those encoding GM-
multipotent progenitors present in the donor fetal liver CSFR and G-CSFR are expressed in multipotential pro-
preparations. The donor-derived erythrocytes are not genitors before myeloid specification. For example,
merely transplanted erythrocytes or the progeny of lin- Mac-1, a myeloid-specific marker, is expressed at low
eage committed progenitors, such as CFU-E, since levels on fetal HSCs (Morrison et al., 1995).
these cells were removed by osmotic lysis prior to im- B cell development is blocked at an extremely early
plantation. The failure of PU.12/2 mutant fetal progeni- step in the absence of PU.1. Previously, we demon-
tors to provide long-term radioprotection may be due strated a failure to initiate heavy and light chain rear-
to one of the following possibilities. First, myeloid cells, rangement as well as to properly activate expression of
which PU.12/2 progenitors cannot produce, may be es- B lineage genes such as mb-1, B29, VpreB, l5, Rag-1,
sential for radioprotection.The essential requirement for and Rag-2 (Scott et al., 1994). We now show that PU.1
myeloid cells is supported by the lack of viable myeloid- mutant multipotential progenitors cannot proliferate and
deficient animals. A second possibility is that PU.12/2 differentiate into pro±B cells in response to stromal cell
fetal liver hematopoietic progenitors cannot be main- contact and signaling by IL-7. The mutant progenitors
tained on a long term basis in the bone marrow microen- may lack one or more receptors required for productive
vironment. The inability of PU.12/2 ES cells to contribute interaction with the stromal layer.
to any hematopoietic lineages in adult chimeras sup- The relationship between the transcription factors
ports this hypothesis. PU.1 and Ikaros,both of which regulate the specification
The cell-intrinsic defect in lymphoid and myeloid pro- of lymphoid progenitors, is particularly intriguing. We
genitors caused by the PU.1 mutation manifests in vitro show that PU.1 does not directly or indirectly regulate
as a failure of such progenitors to either proliferate and/ Ikaros expression since the latter gene continues to be
or differentiate. Colony-forming assays in semisolid me- expressed in PU.1 mutant embryos (Figure 6). Thus,
dia were used to examine erythroid, megakaryoid, and the lymphoid defect in PU.1 mutant embryos cannot
myeloid progenitors from day 15.5 embryos. Whereas be attributed to loss of Ikaros expression. Conversely,
the frequencies of erythroid and megakaryoid progeni- these results argue that Ikaros is not sufficient for lym-
tors were unaffected by the PU.1 mutation, myeloid pro- phopoiesis. Ikaros may function to specify lymphoid
genitors were completely absent (Table 2). B lineage fates in a PU.1-dependent multipotential progenitor. Al-
progenitor frequencies were determined by plating with ternatively, the two genes may function in the same
S17 stromal cells and IL-7 (Figure 5). Unlike their wild- multipotential progenitor in a combinatorial manner to
type or heterozygous counterparts, PU.1 mutant pro- specify lymphoid fates. Interpretation of the PU.1, Ikaros,
genitors failed to give rise to B lineage cells, in vitro. and c-myb mutant phenotypes suggests an ordered hi-
Mutation of the PU.1 gene results in a 5-fold decrease erarchical scheme for hematopoiesis that is fundamen-
in the AA4.11, Lin2 progenitor population in the fetal tally different from the traditional model (Singh, 1996).
liver. This population has been shown to be highly en- This scheme involves sequential and progressive re-
riched for bipotential precursors of B cells and macro- striction of the developmental potential of the stem cell,
phages (Cumano et al., 1992). Our analyses verified that mediated by a hierarchy of transcriptional regulators.
the AA4.11, Lin2 population from PU.11/1 or PU.11/2 As this manuscript was being completed, an inde-
embryos was enriched for macrophage and B lineage pendent PU.1 gene-targeting study was described
progenitors (Table 2 and Figure 5). Furthermore, this (McKercher et al., 1996). In that report, the PU.1 locus
progenitor population was capable of differentiating into was mutated by inserting a neo gene into exon 5 without
B lineage and myeloid cells when plated with S17 stro-
deleting exon sequence encoding the DNA-binding do-
mal cells and IL-7 (Table 3). In contrast to their PU.11/1
main. Comparison with the phenotype of our mutation
or PU.11/2 counterparts, PU.1 mutant AA4.11, Lin2 pro-
(Scott et al., 1994; Olson et al., 1995) reveals many simi-
genitors neither proliferated nor differentiated under
larities and two significant differences. Importantly,bothconditions promoting myeloid or B lymphoid develop-
mutations in the PU.1 gene result in a block to lympho-ment. These results along with experiments demonstra-
and myelopoiesis in the fetal liver and thymus. However,ting a cell-autonomous requirement strongly suggest
the mutation reported by McKercher et al. (1996) doesthat the transcription factor PU.1 functions at the level
not result in late embryonic lethality (day 18). In thisof a multipotential progenitor that can give rise to both
case, PU.1 mutant pups are born but appear to die ofmacrophages and B cells in vitro. Furthermore, they
septicemia within 24±48 hr. With antibiotic treatment,imply that the lymphoid and myeloid lineages develop
PU.1 mutant mice were maintained for up to 17 days.from a common hematopoietic progenitor not shared
Under these conditions, T cell development occurs butwith erythrocytes and megakaryocytes.
is delayed. Single-positive (CD41 or CD81) thymocytesThe molecular defects caused by the PU.1 mutation
are detectable in day 8 PU.1 mutant pups, albeit atin multipotential progenitors remain to be elucidated.
5- to 10-fold lower levels than control littermates. ThePreviously we have shown, using RT-PCR analysis, that
differences in the two phenotypes are instructive andPU.1 is not essential for early myeloid gene expression
are due to distinct mutant alleles of the PU.1 gene. Webut is required for expression of genes associated with
note that our allele does not express any detectableterminal myeloid differentiation (Olson et al., 1995).
PU.1 protein product. Similar data for the allele de-Since these results were obtained with RNA from PU.1
scribed by McKercher et al. (1996) are not available.mutant fetal liver or embryoid bodies, they do not neces-
sarily imply that specification of myeloid progenitors Therefore, it remains possible that the phenotype of the
Immunity
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dithiothreitol, 0.55% ammonium hydroxide) and agitated to lyse thePU.1 mutation described by McKercher et al. is due to
red blood cells. Samples were applied to cellulose acetate platesa truncated PU.1 protein. Furthermore, we have pre-
(Helena Laboratories) and electrophoresed in 0.18 M Tris, 0.1 Mviously demonstrated complementation of our PU.1 al-
boric acid, 0.002 M EDTA for 40 min at 300 V. The plates were
lele in mutant ES cells using a PU.1cDNA-based expres- stained in 1% Ponceau plus 5% trichloroacetic acid for 10 minutes,
sion construct (Olson et al., 1995). Thus the phenotype rinsed in 30% acetic acid/70% ethanol, and air dried.
of our mutation is due to loss of PU.1 function.
Adoptive Transfer Analysis
Experimental Procedures Recipient animals (C57BL/6-Ly 5.1) were exposed to 1200 rad in a
single dose from a 137Cs source. Donor cells (Ly 5.21) were prepared
Mouse Strains as single-cell suspensions (107/ml) in phosphate-buffered saline
Male and female PU.11/2 mice were mated to produce PU.11/1, (PBS) from day 16.5 PU.11/1, PU.11/2, or PU.12/2 fetal livers. Follow-
PU.11/2, and PU.12/2 embryos for these studies. The presence of ing treatment with ACK lysis buffer, 106 cells were introduced by
a vaginal plug on the morning after matings was taken as day 0.5 retroorbital injection into recipient animals under anesthesia. After
of gestation. All embryos were genotyped by Southern blot analysis transplantation, the animals were maintained on water containing
of genomic DNA using a PU.1 cDNA probe (Scott et al., 1994). polymixin B sulfate (106 U/L). Peripheral blood and bone marrow
C57BL/6-Ly 5.1 mice were obtained from the Frederick Cancer Re- samples obtained from recipient mice were analyzed for donor-
search Institute (Frederick, MD). The Ly 5 nomenclature has been derived hematopoietic cells by two-color FACS using Ly 5.2-FITC
recently changed. Our designations follow the revised nomenclature and B220-PE or CD11b-PE specific MAbs. Contribution to the ery-
of Jackson Laboratories. throid lineage by the donor cells was determined by examining the
expression of Hbb isoforms as described above.
Western Blot Analysis of PU.1 Protein
Full-length PU.1 and the N-terminal (amino acids 1±198) segment Enrichment of Multipotent Progenitor Cells
were generated by in vitro transcription/translation as described by from the Fetal Liver
Brass et al. (1996). Protein extracts were prepared from the spleen Single-cell suspensions from day 14.5 fetal livers were prepared in
and thymus of PU.11/1 and PU.11/2 mice and from the fetal livers complete RPMI-1640 media. An aliquot of each sample was stained
of PU.11/1, PU.11/2, and PU.12/2 embryos. Proteins were resolved
for CD11b by FACS analysis. The presence of CD11bbright cells was
by SDS±polyacrylamide gel electrophoresis and electrotransfered
used to distinguish PU.11/1 and PU.11/2 embryos from PU.12/2 em-to an Immobilon membrane (Millipore). The blotted membrane was
bryos. PU.11/1 and PU.11/2 samples were pooled as were PU.12/2incubated with an affinity-purified rabbit anti-PU.1 antibody. The
samples for some of the analysis. All putative genotypes assignedanti-PU.1 antibody was prepared by immunizing rabbits with a full-
by FACS analysis were confirmed by Southern blotting. Fetal liverlength bacterial PU.1±glutathione S-transferase (GST) fusion protein
suspensions were initially incubated at a cell density of 5 3 106 cell/and subsequently purified on a PU.1±GST affinity column. Immuno-
ml with anti-AA4.1-biotin MAb. After the cells were washed withreactive proteins were detected using an enhanced chemilumines-
PBA (PBS 1 0.05% bovine serum albumin, 1% sodium azide), acence visualization system (Amersham).
second staining step was performed with an anti-lineage-PE cock-
tail (B220, CD3e, CD4, CD5, CD8a, Gr-1, and TER-119), anti-CD11b-Antibodies/FACS Analysis
TRI-COLOR (TC) MAb, and streptavidin-FITC. After a final wash inFlow cytometry analysis was performed on single-cell suspensions
PBS, the cells were resuspended in complete RPMI-1640 mediaof fetal liver, thymus, bone marrow, and blood prepared by standard
containing 5% fetal bovine serum prior to sorting. Gates were setmethods (Scott et al., 1994). Cells were stained with fluorescein
using control staining reactions containingno antibody, AA4.1-FITC,isothiocyanate (FITC)± or phycoerythrin (PE)±conjugated antibodies
lineage-PE cocktail, or Mac-1-TRI-COLOR MAb alone. The gateand analyzed on a dual laser cell sorter (FACSCAN, Becton Dickin-
settings removed cellular debris, aggregates, dead cells, and theson). Propidium iodide uptake and scatter-gating for size were used
bulk of erythrocytes. The stained cells were sorted by three-colorto exclude dead cells from the analysis. Monoclonal antibodies
flow cytometry using a FACStarPlus machine and Lysis II software(MAb) RA3±6B2 (B220), 145±2C11 (CD3-e), RM4±5 (CD4), RB6±8C5
(Becton Dickinson). The gated AA4.11/Lin2/CD11b2/dim cells(CD5), 53±6.7 (CD8a), RB6±8C5 (Gr-1), M1/70 (CD11b/Mac-1), 30C7
(AA4.11, Lin2) were collected for subsequent experiments. CD11bdim(Ly-9.1), and TER-119 were used according to the instructions of
cells were included in the multipotential progenitor population sincethe supplier (Pharmingen). Goat anti-mouse IgM-FITC was obtained
from Southern Biotechnology, and the M1/70 MAb (CD11b/Mac-1) this lineage marker is expressed at low levels in fetal HSCs (Morrison
conjugated with TRI-COLOR was purchased from Caltag Labora- et al., 1995). Reanalysis of sorted cells by FACS indicated that this
tories. The AA4.1 MAb (McKearn et al., 1984) was harvested from scheme yielded populations that were more than 95% pure based
hybridoma culture supernatants by ammonium sulfate precipitation on AA4.1 and lineage surface marker expression.
and purified by protein-G chromatography (Pierce Chemical Co.).
The antibody was biotinylated with aminohexanoyl-biotin-N-hydroxy- Methylcellulose Clonogenic Assays
succinimide ester (Zymed Laboratories) according to the manufac- Whole fetal liver suspensions (2 3 105) or sorted cells (500) were
turer's instructions and visualized with streptavidin-FITC (Zymed plated in 1.25 ml of complete Methocult medium (Stem Cell Technol-
Laboratories). The Ly5.2-FITC MAb was a gift from I. L. Weissman ogy) or a methylcellulose (StemCell Technology) supplemented with
(Stanford University, Stanford, CA). 0.01% penicillin/streptomycin, 2 mM L-glutamine, 100 mm b-mer-
captoethanol, 2 U/ml erythropoietin (R and D Systems), and 1.3%
Generation of Chimeric Mice pokeweed mitogen stimulated spleen cell±conditioned medium
Chimeras were generated by injecting either wild-type or PU.12/2 (Stem Cell Technology). After 5±7 days of incubation, colonies were
ES cells into C57BL/6 blastocysts as described by Papaioannou
scored and their identity confirmed by May-Grunwald-Giemsa (Diff-and Johnson (1993). ES cell± and blastocyst-derived cells were dis-
Quik, Baxter) staining of cytospin preparations.tinguished by FACS using the Ly 9.1 MAb, which recognizes only
the progeny of 129SV ES cells (Nakayama et al., 1993).
S17 and IL-7 Cultures
The S17 and IL-7 cultures for 24- and 96-well plates were performedGPI and Hbb Assays
as described by Cumano and Paige (1992). In brief, sorted cellsTissue samples for GPI analysis were lysed by repeated rounds of
contained in RPMI-1640 supplemented with 5% fetal bovine serum,freezing and thawing. One microliter aliquots were electrophoresed
50 mM b-merocaptoethanol, 0.01% penicillin-streptomycin, 2 mMat 48C in Tris-glycine buffer (25 mM Tris, 200 mM glycine [pH 8.5])
L-glutamine and IL-7 (250 U/ml; Genzyme) were cultured on irradi-for 1.5 hr at 150 V and stained for GPI activity as described by
ated S17 cells (2000 rad). B cell precursor frequency assays werePapaioannou and Johnson (1993). Cellulose acetate electrophoresis
performed in 48 wells of 96-well plates. After 5 days of culturing,of cystamine-modified Hbb isoforms was performed as previously
fresh IL-7±containing medium was added to the wells, and individualdescribed (Whitney, 1978). Peripheral blood samples were added to
cystamine lysis buffer (12.5 mg/ml cystamine dihyrochloride, 1 mM wells were examined for proliferating cells after 8±9 days in culture.
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RT-PCR Analysis The purification and characterization of fetal liver hematopoietic
stem cells. Proc. Natl. Acad. Sci. 92, 10302±10306.RT-PCR analysis was performed, as described by Scott et al. (1994),
with fetal liver RNA from PU.11/1, PU.11/2, and PU.12/2 embryos. Morrison, S.J., and Weissman, I.L. (1994). The long-term repopulat-
Ikaros transcripts were amplified with the following primers: CACTA ing subset of hematopoietic stem cells is deterministic and isolat-
CCTCTGGAGCACAGC and TCTGAGGCATAGAGCTCTTAC. Pax-5 able by phenotype. Immunity 1, 661±673.
transcripts were amplified using the following primers: CGGGTCAG Mucenski, M., Mclain, K., Kier, A., Swerdlow, S., Schreiner, C., Miller,
CCATGG TTG and GTGCTGCCTCTCAAACACG. T., Pietryga, D., Scott W., and Potter, S. (1991). A functional c-myb
gene is required for normal murine fetal hepatic hematopoiesis. Cell
Received December 6, 1996; revised February 11, 1997. 65, 677±689.
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